CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 20, 2006--AVONEX® (Interferon beta 1a), the most prescribed multiple sclerosis (MS) therapy worldwide may now be administered with a needle that is 20 percent shorter and thinner than the currently approved needle. People living with MS and taking or considering AVONEX may speak with their healthcare provider to see if the smaller needle is appropriate for them.
